The level of expression and activation of Src was assessed by immunofluorescence in non-adherent cell populations derived from ascites of unmatched advanced-stage recurrent serous ovarian cancer patients, previously treated with chemotherapy (n = 6) and advanced-stage chemonaïve serous ovarian cancer patients (n = 8) (Table 2). This evidence concerns the gene SRC and ovarian serous adenocarcinoma.